Anagenics Limited

AN1

AU0000198095

Personal Products

Delayed Australian S.E. Other stock markets 10:16:10 2024-04-28 pm EDT			5-day change	1st Jan Change
0.01 ^AUD	+11.11%		+11.11%	-47.37%

Mar. 08	Anagenics Appoints CEO	MT
Feb. 26	Anagenics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	CI

Anagenics Limited Appoints Scott Mitchell Greasley as Director

July 07, 2022 at 07:38 pm EDT

Anagenics Limited announced appointment of Scott Mitchell Greasley as director of the company. Date of appointment is on 8 July 2022.

Latest news about Anagenics Limited

Anagenics Appoints CEO	Mar. 07	MT
Anagenics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 26	CI
Anagenics Completes Placement to Raise AU$1.3 Million	Feb. 06	MT
Anagenics Grows Fiscal H1 Revenue	Jan. 30	MT
Anagenics Acquires Face Medi Group	23-10-02	MT
Anagenics Limited Announces Board Executive Changes	23-10-01	CI
Anagenics Limited completed the acquisition of Face MediGroup.	23-10-01	CI
Anagenics Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-29	CI
Anagenics Limited agreed to acquire Face MediGroup for AUD 1.3 million.	23-08-21	CI
Anagenics Appoints CEO/Managing Director	23-03-28	MT
Anagenics Limited Appoints Scott Greasley as Managing Director, Effective from 1 April 2023	23-03-28	CI
Anagenics Limited Announces CEO Changes	23-03-28	CI
Anagenics Raises Funds from Institutional Entitlement Offer	23-02-16	MT
Anagenics Raising AU$3.2 Million Via Entitlement Offer	23-02-14	MT
Anagenics Limited Appoints Karen Matthews as Non-Executive Director	23-02-13	CI
Anagenics Limited Reports Earnings Results for the Half Year Ended December 31, 2022	23-02-13	CI
Anagenics Limited acquired Uspa Global Pty. Ltd. from BWX Limited.	22-12-08	CI
Anagenics Approves the Election of Mr. Alexander Beard as A Director	22-11-28	CI
Anagenics Limited Announces Resignation of Dennis Eck as Director	22-10-16	CI
Anagenics Limited Reports Earnings Results for the Full Year Ended June 30, 2022	22-08-24	CI
Anagenics Limited Reports Earnings Results for the Full Year Ended June 30, 2022	22-08-24	CI
Anagenics Grows Fiscal Q4 Revenue 11%	22-07-25	MT
Anagenics Limited Appoints Scott Mitchell Greasley as Director	22-07-07	CI
Anagenics Records 121% Jump in Fiscal Q3 Revenue	22-04-28	MT
Anagenics Promotes Financial Controller to Acting CEO	22-02-28	MT

Anagenics Limited is an Australia-based health and beauty-tech company. The Company offers a range of clinically validated anti-ageing and wellness products developed in-house or sourced from premium international brands. The Company, through its wholly owned subsidiary Advangen Pty Ltd, develops, manufactures and markets anti-aging products globally, with its FGF5 inhibitor hair health and hair growth products sold worldwide. The flagship anti-aging hair care range, marketed as evolis, Advangen Jo-Ju and Lexilis brands, is sold in Japan, the United States of America and Australia. The Companyâs subsidiary is BLC Cosmetics Pty Limited, which is the distributor of international and local skin care and wellbeing brands.

Sector

Personal Products

Calendar

2024-08-27 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Personal Products

	1st Jan change	Capi.
ANAGENICS LIMITED	-47.37%	2.71M
PROCTER & GAMBLE COMPANY	+10.32%	381B
UNILEVER PLC	+8.03%	129B
HINDUSTAN UNILEVER LIMITED	-16.39%	62.59B
ESTEE LAUDER	+0.37%	52.86B
KENVUE INC.	-11.47%	36.11B
BEIERSDORF	+2.76%	33.57B
ESSITY AB	+9.68%	17.29B
GODREJ CONSUMER PRODUCTS LIMITED	+7.68%	14.75B
DABUR INDIA LIMITED	-9.06%	10.82B

Other Personal Products